Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
25 avr. 2024 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first...
Andrew Fisher Joins Verona Pharma as General Counsel
04 mars 2024 02h00 HE
|
Verona Pharma plc
Verona Pharma announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team.
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 févr. 2024 02h00 HE
|
Verona Pharma plc
PDUFA Target Action Date for ensifentrine of June 26, 2024 Commercialization preparations advance Strong balance sheet supports commercialization and Company's growth Conference call today at 9:00...
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
15 févr. 2024 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth...
Michael Austwick Joins Verona Pharma as Non-Executive Director
01 févr. 2024 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director. ...
Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at...
Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital
02 janv. 2024 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (the “Company”),...
Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award
17 nov. 2023 02h00 HE
|
Verona Pharma plc
Verona Pharma plc announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023' at the SCRIP awards.
Verona Pharma Announces November 2023 Investor Conference Participation
08 nov. 2023 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at...
Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
02 nov. 2023 03h04 HE
|
Verona Pharma plc
US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations supported by strong balance sheet Conference...